CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
(RTTNews) - Intellia Therapeutics, Inc. (NTLA) announced that the U.S. FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial evaluating nexiguran ziclumeran (nex-z) in hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results